The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria

American Journal of Gastroenterology

Volumn 105, Issue 3, 2010, Pages 599-609

  Leoni, Simona ^a   Piscaglia, Fabio ^a   Golfieri, Rita ^b   Camaggi, Valeria ^a   Vidili, Gianpaolo ^a   Pini, Patrizia ^a   Bolondi, Luigi ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FERUCARBOTRAN; GADOLINIUM PENTETATE; IOMEPROL; IOMERON 350; NONIONIC CONTRAST MEDIUM; SONOVUE; SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ADULT; AGED; CANCER DIAGNOSIS; CLINICAL PRACTICE; COMPUTED TOMOGRAPHY SCANNER; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; IMAGING SYSTEM; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER NODULE; MAJOR CLINICAL STUDY; MALE; MEDICAL TECHNOLOGY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEEDLE; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; THREE DIMENSIONAL IMAGING; ULTRASOUND; VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; FERROSOFERRIC OXIDE; GADOLINIUM DTPA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHOLIPIDS; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SULFUR HEXAFLUORIDE; TOMOGRAPHY, SPIRAL COMPUTED; ULTRASONOGRAPHY;

EID: 77949267080     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.654     Document Type: Review

References (22)

1. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430
2. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236
3. Terminology of Nodular Hepatocellular Lesions. International Working Party. Hepatology 1995;22:983-993
4. Piscaglia F, Bolondi L. Recent advances in the diagnosis of hepatocellular carcinoma. Hepatol Res 2007;37 (Suppl 2):S178-92.
5. Burrel M, Llovet JM, Ayuso C, et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation:an explant correlation. Hepatology 2003;38:1034-1042
6. Ward J, Guthrie JA, Scott DJ, et al. Hepatocellular carcinoma in the cirrhotic liver:double-contrast MR imaging for diagnosis. Radiology 2000;216:154-162
7. Tomemori T, Yamakado K, Nakatsuka A, et al. Fast 3D dynamic MR imaging of the liver with MR SmartPrep:comparison with helical CT in detecting hypervascular hepatocellular carcinoma. Clin Imaging 2001;25:355-361
8. Bolondi L, Gaiani S, Celli N, et al. Characterization of small nodules in cirrhosis by assessment of vascularity:the problem of hypovascular hepatocellular carcinoma. Hepatology 2005;42:27-34.
9. Quaia E, Calliada F, Bertolotto M, et al. Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble contrast agent:diagnostic performance and confidence. Radiology 2004;232:420-430
10. Nicolau C, Catala V, Vilana R, et al. Evaluation of hepatocellular carcinoma using SonoVue, a second generation ultrasound contrast agent:correlation with cellular differentiation. Eur Radiol 2004;14:1092-1099
11. Gaiani S, Celli N, Piscaglia F, et al. Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. J Hepatol 2004;41:421-426
12. Kim YK, Kwak HS, Kim CS, et al. Hepatocellular carcinoma in patients with chronic liver disease:comparison of SPIO-enhanced MR imaging and 16-detector row CT. Radiology 2006;238:531-541
13. Lutz AM, Willmann JK, Goepfert K, et al. Hepatocellular carcinoma in cirrhosis:enhancement patterns at dynamic gadolinium-and superparamagnetic iron oxide-enhanced T1-weighted MR imaging. Radiology 2005;237:520-528
14. Vogl TJ, Hammerstingl R, Schwarz W, et al. Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient. Invest Radiol 1996;31:696-708.
15. Reimer P, Jahnke N, Fiebich M, et al. Hepatic lesion detection and characterization: value of nonenhanced MR imaging, superparamagnetic iron oxide-enhanced MR imaging, and spiral CT-ROC analysis. Radiology 2000;217:152-158
16. Bolondi L, Correas JM, Lencioni R, et al. New perspectives for the use of contrast-enhanced liver ultrasound in clinical practice. Dig Liver Dis 2007;39:187-195
17. Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis:prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008;47:97-104.
18. Hayashi M, Matsui O, Ueda K, et al. Progression to hypervascular hepatocellular carcinoma:correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. Radiology 2002;225:143-149
19. Kudo M. Imaging diagnosis of hepatocellular carcinoma and premalignant/ borderline lesions. Semin Liver Dis 1999;19:297-309.
20. Yukisawa S, Okugawa H, Masuya Y, et al. Multidetector helical CT plus superparamagnetic iron oxide-enhanced MR imaging for focal hepatic lesions in cirrhotic liver:a comparison with multi-phase CT during hepatic arteriography. Eur J Radiol 2007;61:279-289
21. Saito K, Kotake F, Ito N, et al. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma:quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci 2005;4:1-9.
22. Kudo M, Okanoue T, Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan:consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007;72 (Suppl 1):2-15.